FDA Advisory Committee Unanimously Recommends First mRNA Seasonal Flu Vaccine

The Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) has unanimously recommended the approval of Moderna's investigational mRNA-1010 seasonal influenza vaccine for adults aged 50 and older.[1][5]

The 9-0 vote, delivered on June 18, 2026, marks a watershed moment in preventative medicine. If the FDA follows the committee's recommendation by its August 5 target date, mRNA-1010 will become the first mRNA-based seasonal flu vaccine licensed in the United States.[2][6]

The primary claim supporting this shift is that mRNA technology offers a significant speed advantage over traditional manufacturing methods. Traditional flu vaccines rely on incubating the virus in chicken eggs, a slow and labor-intensive process that takes approximately six months from start to finish.[6]

Because of this long lead time, the World Health Organization and the FDA must predict which flu strains will circulate in the winter during the preceding spring. If the virus mutates significantly during those six months, the resulting vaccine can suffer from a severe "mismatch," leading to lower efficacy rates.[5]

According to the FDA briefing documents, mRNA vaccines can be manufactured in just two to three months. This compressed timeline allows scientists to wait much longer before locking in the vaccine strains, dramatically reducing the risk of a mismatch between the vaccine and the actual circulating virus.[1][5]

The committee's endorsement was anchored by the FLUENT Phase 3 clinical trial, which enrolled 40,703 participants aged 50 and older to test the efficacy claim directly.[4]

Published in The New England Journal of Medicine, the double-blind, active-controlled study compared mRNA-1010 against a licensed standard-dose flu vaccine to determine if the new technology provided superior protection.[3]

The evidence showed a relative vaccine efficacy of 26.6% against protocol-defined influenza-like illness caused by influenza A or B. This means the mRNA vaccine prevented over a quarter more symptomatic infections than the standard shot.[3]

Furthermore, the data indicated a 47.9% reduction in flu-related emergency room visits, hospitalizations, and urgent care use compared to the standard comparator, providing strong evidence that the vaccine prevents severe outcomes.[2][3]

The evidence regarding safety is robust but comes with specific caveats regarding reactogenicity. Trial data revealed that systemic and local reactions were more common with the mRNA shot than with traditional vaccines.[3][6]

Specifically, 65.8% of participants reported injection-site pain, 45.1% experienced fatigue, and 37.8% reported headaches following the administration of the mRNA-1010 dose.[3][4]

However, the FDA advisory panel concluded that these events were predominantly mild-to-moderate and self-limiting. The side effect profile closely mirrors the reactogenicity seen with mRNA COVID-19 vaccines, which the public and medical community have grown accustomed to managing.[1][5]

While the overall vote was unanimous, the evidence pack presented to the FDA did contain notable gaps that require transparent ongoing monitoring.[6]

FDA scientists noted in their briefing documents that the trial's observation window was relatively short. This leaves open questions about the long-term durability of the immune response—specifically, whether the antibody protection wanes before the end of a long winter flu season.[2][5]

Additionally, the trial captured a small number of confirmed influenza B cases, making the statistical confidence in the vaccine's efficacy against those specific strains slightly weaker than for influenza A.[2][6]

To address these uncertainties in the oldest and most vulnerable populations, Moderna is seeking a split regulatory pathway: standard approval for adults aged 50 to 64, and accelerated approval for those 65 and older.[1][2]

The accelerated approval pathway for the 65-plus demographic will require Moderna to conduct post-marketing head-to-head confirmatory studies. These studies must compare the mRNA shot against the specialized high-dose flu vaccines currently recommended for seniors.[2][5]

Despite these conditions, public health experts view the unanimous vote as a critical validation of the mRNA platform's versatility beyond pandemic response. The ability to rapidly spin up targeted vaccines is seen as a major upgrade to global health infrastructure.[1][6]

With a final FDA decision expected by August 2026, pharmacies and healthcare providers are already preparing their supply chains and patient communication strategies.[2][6]

If approved on schedule, this new, egg-free immunization option will be available in clinics and pharmacies in time for the 2026-2027 respiratory virus season, offering older adults a highly effective new tool against a familiar threat.[1][6]